Frontage Holdings Corporation
Frontage Holdings Corporation, a contract research organization, provides laboratory and related services to pharmaceutical, biotechnology, and agrochemical companies. It offers drug discovery services comprising medicinal chemistry, pharmacology, and efficacy, as well as absorption, distribution, metabolism, and excretion (ADME) screening. The company also provides drug metabolism and pharmacoki… Read more
Frontage Holdings Corporation (FGHQF) - Net Assets
Latest net assets as of June 2025: $341.44 Million USD
Based on the latest financial reports, Frontage Holdings Corporation (FGHQF) has net assets worth $341.44 Million USD as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($544.27 Million) and total liabilities ($202.83 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $341.44 Million |
| % of Total Assets | 62.73% |
| Annual Growth Rate | 43.32% |
| 5-Year Change | 15.72% |
| 10-Year Change | N/A |
| Growth Volatility | 163.23 |
Frontage Holdings Corporation - Net Assets Trend (2016–2024)
This chart illustrates how Frontage Holdings Corporation's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Frontage Holdings Corporation (2016–2024)
The table below shows the annual net assets of Frontage Holdings Corporation from 2016 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $334.27 Million | -3.15% |
| 2023-12-31 | $345.15 Million | +2.92% |
| 2022-12-31 | $335.36 Million | +3.83% |
| 2021-12-31 | $322.99 Million | +11.81% |
| 2020-12-31 | $288.87 Million | +8.89% |
| 2019-12-31 | $265.28 Million | +507.96% |
| 2018-12-31 | $43.63 Million | +44.39% |
| 2017-12-31 | $30.22 Million | +60.91% |
| 2016-12-31 | $18.78 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Frontage Holdings Corporation's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 11084400000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | $109.87 Million | 32.99% |
| Common Stock | $19.99K | 0.01% |
| Other Comprehensive Income | $-4.22 Million | -1.27% |
| Other Components | $227.34 Million | 68.27% |
| Total Equity | $333.00 Million | 100.00% |
Frontage Holdings Corporation Competitors by Market Cap
The table below lists competitors of Frontage Holdings Corporation ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Grown Rogue International Inc
OTCQB:GRUSF
|
$53.77 Million |
|
F & M Bank Corp
OTCQX:FMBM
|
$53.77 Million |
|
Jeil Pharmaceutical Co Ltd
KO:271980
|
$53.77 Million |
|
NSTS Bancorp Inc
NASDAQ:NSTS
|
$53.77 Million |
|
Future Vision II Acquisition Corporation Units
NASDAQ:FVNNU
|
$53.76 Million |
|
Cheryong Industrial Co.Ltd
KQ:147830
|
$53.72 Million |
|
Creative Newtech Limited
NSE:CREATIVE
|
$53.71 Million |
|
Payfare Inc
OTCQX:PYFRF
|
$53.71 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Frontage Holdings Corporation's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 342,503,000 to 333,005,000, a change of -9,498,000 (-2.8%).
- Net income of 791,000 contributed positively to equity growth.
- Share repurchases of 11,203,000 reduced equity.
- New share issuances of 7,218,000 increased equity.
- Other comprehensive income decreased equity by 22,460,048.
- Other factors increased equity by 16,156,048.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $791.00K | +0.24% |
| Share Repurchases | $11.20 Million | -3.36% |
| Share Issuances | $7.22 Million | +2.17% |
| Other Comprehensive Income | $-22.46 Million | -6.74% |
| Other Changes | $16.16 Million | +4.85% |
| Total Change | $- | -2.77% |
Book Value vs Market Value Analysis
This analysis compares Frontage Holdings Corporation's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.62x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 6.71x to 0.62x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | $0.02 | $0.10 | x |
| 2018-12-31 | $0.02 | $0.10 | x |
| 2019-12-31 | $0.14 | $0.10 | x |
| 2020-12-31 | $0.14 | $0.10 | x |
| 2021-12-31 | $0.15 | $0.10 | x |
| 2022-12-31 | $0.16 | $0.10 | x |
| 2023-12-31 | $0.17 | $0.10 | x |
| 2024-12-31 | $0.16 | $0.10 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Frontage Holdings Corporation utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.24%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.31%
- • Asset Turnover: 0.46x
- • Equity Multiplier: 1.66x
- Recent ROE (0.24%) is below the historical average (13.84%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | 35.39% | 13.66% | 1.14x | 2.27x | $4.77 Million |
| 2017 | 33.64% | 14.47% | 1.23x | 1.89x | $7.14 Million |
| 2018 | 25.76% | 13.52% | 1.07x | 1.78x | $6.88 Million |
| 2019 | 6.96% | 18.25% | 0.32x | 1.19x | $-8.04 Million |
| 2020 | 5.96% | 13.63% | 0.33x | 1.33x | $-11.64 Million |
| 2021 | 5.76% | 10.02% | 0.39x | 1.49x | $-13.55 Million |
| 2022 | 7.73% | 10.25% | 0.46x | 1.65x | $-7.54 Million |
| 2023 | 3.16% | 4.16% | 0.45x | 1.67x | $-23.44 Million |
| 2024 | 0.24% | 0.31% | 0.46x | 1.66x | $-32.51 Million |
Industry Comparison
This section compares Frontage Holdings Corporation's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Frontage Holdings Corporation (FGHQF) | $341.44 Million | 35.39% | 0.59x | $53.77 Million |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |